A
A
Home

Press Releases

2023

argenx to Present at Upcoming Investor Conferences
February 24, 2023
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
January 27, 2023
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
January 16, 2023
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
January 9, 2023
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
January 3, 2023
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference

2022

argenx Appoints Ana Cespedes to Board of Directors
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
November 30, 2022
argenx Enters Into Agreement To Acquire Priority Review Voucher
November 22, 2022
argenx Announces U.S. FDA Acceptance of Biologics License Application for Subcutaneous Efgartigimod in Generalized Myasthenia Gravis with Priority Review
November 7, 2022
argenx to Present at Upcoming Investor Conferences
October 28, 2022
argenx announces Extraordinary General Meeting of Shareholders on December 12, 2022